Phase 4 N=40 Randomized Quadruple-blind Treatment

Effects of Modafinil in Methamphetamine Dependence

Methamphetamine Dependence

Bottom Line

View on ClinicalTrials.gov: NCT00751023 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2019

Primary outcome: Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Modafinil (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Medical University of South Carolina
Primary completion: Jul 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Participants With Methamphetamine-positive Urine Drug Screens	85; 65	—
SECONDARY Percent Change in California Verbal Learning Test From Baseline to Study Endpoint	20.6; 14.8	—
SECONDARY Percent Change in Symbol Digit Modalities Test From Baseline to Study Endpoint	6.4; 10.0	—
SECONDARY Percent Change in Paced Auditory Serial Addition Test Scores From Baseline to Study Endpoint	11.3; 28.5	—
SECONDARY Score on the Wisconsin Card Sort Test	44.6; 41.9	—
SECONDARY Percent Change in the Grooved Pegboard Test Score From Baseline to Study Endpoint	10.8; 65.0	—
SECONDARY Percent Change in Shipley Institute of Living Scale Scores From Baseline to Study Endpoint	4.1; 4.6	—
SECONDARY Percentage Change in Beck Depression Inventory Scores	-58.4; -43.5	—

Summary

Methamphetamine dependence is a serious public health problem with no pharmacologic treatments currently available. Relapse rates are high in this population. Exposure to cues previously associated with methamphetamine use may induce profound craving in abstinent individuals. Chronic methamphetamine abuse is associated with selective cognitive deficits that may undermine successful participation in psychosocial treatments. Medications which improve cognitive deficits in methamphetamine-dependent individuals may improve abstinence rates, especially in the critical early period of recovery. Modafinil is an atypical stimulant medication with evidence to support its use in treating cocaine dependence and attention deficit/hyperactivity disorder. The proposed studies are designed to evaluate modafinil as a potential treatment for methamphetamine dependence and its cognitive sequelae.

Eligibility Criteria

Inclusion Criteria

Subjects must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
Subjects must meet DSM-IV criteria for methamphetamine dependence within the past six months. Subjects may meet criteria for abuse, but not dependence on any other substance with the exception of nicotine. Because of the high comorbidity of methamphetamine and nicotine dependence, excluding nicotine dependence would seriously compromise the feasibility of recruitment. Nicotine use immediately prior to the cue reactivity testing session will be controlled.
Subjects must consent to remain abstinent from all drugs of abuse (except nicotine) for 24 hours prior to the cue reactivity testing sessions.
Subjects must consent to random assignment to the modafinil vs. placebo conditions.

Exclusion Criteria

Women who are pregnant, nursing or of childbearing potential and not practicing an effective means of birth control.
Subjects with evidence of or a history of significant hematological, endocrine, cardiovascular, pulmonary, renal, gastrointestinal, or neurological disease as these conditions may affect heart rate or skin conductance measurement.
Subjects with a history of or current psychotic disorder or bipolar affective disorder as these may impact cue reactivity.
Subjects who are unwilling or unable to maintain abstinence from alcohol and other drugs of abuse (except nicotine) for 24 hours prior the cue procedures.
Subjects meeting DSM-IV criteria for substance dependence (other than nicotine or methamphetamine as appropriate) within the past 60 days.
Subjects currently taking B-blockers, anti-arrhythmic agents, psychostimulants or any other agents known to interfere with heart rate and skin conductance monitoring.
Known or suspected hypersensitivity to modafinil.
Individuals taking medications that could adversely interact with study medications.
Subjects with a history of epilepsy or seizure disorder.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00751023). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.